A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
about
Liposomal delivery systems for intestinal lymphatic drug transportA mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportThe mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transportThe effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps.Formulation, Pharmacokinetic, and Efficacy Studies of Mannosylated Self-Emulsifying Solid Dispersions of Noscapine.Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.Pros and cons of methods used for the prediction of oral drug absorption.Self-nano-emulsifying drug delivery systems: an update of the biopharmaceutical aspects.Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Important effect of food on the bioavailability of oral testosterone undecanoate.Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model.Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
P2860
Q28067324-D8EECE83-8498-47D1-B41A-F58E3184CD7FQ34060125-1735B85A-9167-4B2A-BD81-7D879CBF9BEEQ35458865-F2DB18BF-789F-41C1-A057-63D3201F4969Q35768803-5E642DCB-2EB9-4BF3-9682-831B3FCD25A4Q35891741-2DCAD73F-0E8F-42B4-9B08-5B947DA9C00EQ36748145-D96DD772-17D1-4282-BC69-0820CF3EB518Q37066550-63066E64-340C-4A70-B0CC-38FE60D379FAQ38177366-3E35EC5C-1117-45CA-8A18-6DB7FA899C47Q38306645-3794E0B7-53CF-4336-B051-9A53ACE9441EQ38558905-EEAE81EF-234D-4002-879C-033CA1AF3890Q38926514-5506C262-C78A-4702-AAA1-7F7E67AA93A6Q44356205-B6EDB91A-9977-42A9-96C1-A17FFAD0552CQ44773929-C9FC7BB5-F889-47CC-B78D-AC378A6F1B21Q46633482-9EB8BBC3-CC16-4CD2-B068-CADBBF5C39A6Q50309039-04B93BE7-2763-41F5-B9D9-43FBD11135C1Q51280033-72AAE083-32E8-440B-A88E-671563732A14Q51490836-CE35CD54-BD92-4E30-855A-B23EEADD5DBD
P2860
A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A conscious dog model for asse ...... tic transport of halofantrine.
@en
A conscious dog model for asse ...... tic transport of halofantrine.
@nl
type
label
A conscious dog model for asse ...... tic transport of halofantrine.
@en
A conscious dog model for asse ...... tic transport of halofantrine.
@nl
prefLabel
A conscious dog model for asse ...... tic transport of halofantrine.
@en
A conscious dog model for asse ...... tic transport of halofantrine.
@nl
P2093
P356
P1476
A conscious dog model for asse ...... atic transport of halofantrine
@en
P2093
P304
P356
10.1002/JPS.1110
P407
P577
2001-10-01T00:00:00Z